Nexentis unit MitoCareX evaluates new protein sourcing options for in-vitro research

• Nexentis unit MitoCareX is evaluating additional commercially available approaches to source proteins for in-vitro research.
• Review targets greater flexibility in research materials as MitoCareX advances future in-vitro drug discovery programs.
• Assessment remains early-stage with no assurance any new protein-sourcing approach will be adopted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexentis Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230707PRIMZONEFULLFEED9832362) on September 23, 2026, and is solely responsible for the information contained therein.